| Code | CSB-RA023981MB7HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to HLX-51, targeting TNFRSF4 (tumor necrosis factor receptor superfamily member 4), also known as OX40 or CD134. TNFRSF4 is a costimulatory receptor primarily expressed on activated T cells that plays a critical role in T cell proliferation, survival, and effector function. Upon binding to its ligand OX40L, this receptor enhances T cell-mediated immune responses and promotes long-term T cell memory formation. TNFRSF4 signaling is implicated in various immune-related conditions, including autoimmune diseases, inflammatory disorders, and cancer, where it serves as a key regulator of immune checkpoint pathways.
HLX-51 represents an investigational therapeutic antibody designed to modulate TNFRSF4 activity, with potential applications in immuno-oncology research. This biosimilar antibody provides researchers with a valuable tool for investigating OX40 signaling mechanisms, studying T cell activation and differentiation, and exploring novel immunotherapeutic strategies. It supports studies examining the role of costimulatory pathways in tumor immunity, autoimmune pathogenesis, and vaccine responses.
There are currently no reviews for this product.